• Lawyers
  • Practices
  • COVID-19 Resources
  • Insights
    • Firm News
    • Press Releases
    • Publications
    • Webcasts
    • Podcasts
    • Subscribe
    • Media Contacts
  • Careers
    • Career Opportunities
    • Attorney Development
    • Contact Us
  • About
    • Our Story
    • Awards & Accolades
    • Offices
    • Diversity
    • Pro Bono
    • Alumni
    • Contact Us
  • Biography
  • Education
  • Recent Publications
Profile Picture

Jane M. Love, Ph.D.

Jane
Love

Partner

CONTACT INFO

jlove@gibsondunn.com

TEL:+1 212.351.3922

FAX:+1 212.351.6322

New York

200 Park Avenue, New York, NY 10166-0193 USA

  • Print
  • |
  • Share
  • |
  • vCard

PRACTICE

Intellectual Property Antitrust and Competition Appellate and Constitutional Law Artificial Intelligence and Automated Systems Emerging Companies Environmental, Social and Governance (ESG) FDA and Health Care Fashion, Retail and Consumer Products Life Sciences Litigation Technology Transactions Trade Secrets

BIOGRAPHY

Jane M. Love, Ph.D. is Chair of the Life Sciences practice at Gibson Dunn & Crutcher LLP.  Dr. Love is a partner in the litigation and intellectual property practice groups of Gibson Dunn and is resident in the New York office.

Dr. Love is a first-chair litigator who handles high value patent litigation for pharma and biotech companies including global litigation coordination.  She has extensive experience in Hatch-Waxman and BPCIA litigation.  As a registered patent attorney, Jane is often lead counsel in concurrent Patent Office proceedings.  Jane routinely offers strategic patent prosecution advice and patent diligence advice in connection with high value transactions.

Dr. Love has litigated patent issues in many jurisdictions around the country including Delaware, New Jersey, California, Massachusetts, and others.  Her cases have spanned a wide variety of technologies but of late focus on biologics, therapeutic nucleic acids, and small molecules.  She has advised clients on antibodies, immunotherapies, genetics, vaccines, protein therapies, blood factors, medical devices, diagnostics, gene therapies, RNA therapies, bioinformatics and nanotechnology.  She is a patent attorney registered to practice before the U.S. Patent and Trademark Office and has prosecuted hundreds of patent applications.

Dr. Love is Chambers-rated for Intellectual Property, and has twice been named “Life Sciences MVP” by Law360 (2017 and 2019). The National Law Journal named her a 2020 Health Care/Life Science Trailblazer in recognition for her work representing Novartis AG’s multiple sclerosis drug Gilenya in cases impacting patent owners and challengers across the pharmaceutical and biotech industries. She and her team won “Hatch-Waxman Impact Case of the Year” in 2019 for a case related to patent term extensions and terminal disclaimers which Dr. Love won in Delaware District court and argued before the Federal Circuit. She is consistently named an “IP Star” by Managing IP and is recognized as one of the “world’s leading patent professionals” by IAM Patent. Dr. Love was recognized as “Best in Patent” at the 2018 Euromoney Legal Media Group Women in Business Law Awards. In addition, she has been named in 2017 and 2020 in Legal Media Group’s Expert Guides Guide to the World’s Leading Women in Business Law for Patents.  Dr. Love has been named a “Life Sciences Star” for Intellectual Property by LMG Life Sciences.  She was named one of the “Top 250 Women in IP” by Managing IP in its six most recent lists and was named one of the IP attorneys in the “Top 50 Under 45” list by IP Law & Business in 2008.

Before joining Gibson Dunn, Dr. Love was the Co-Vice Chair of the Intellectual Property Department of Wilmer Hale and associated with that firm in New York since 2001.  For seven years before that, Dr. Love practiced in an IP boutique law firm in New York.

Dr. Love received her Juris Doctor from Fordham University School of Law.  Before practicing law, Dr. Love was a Ph.D. graduate student at the University of Pennsylvania and Thomas Jefferson Medical School in Philadelphia and was a Post-Doctoral Research Fellow at Cornell University Weill Medical College in New York City in molecular biology, pharmacology and cell and developmental biology.

Dr. Love served as a Captain in the U.S. Army Reserve Medical Service Corp from 1991 to 1997.

Representative cases:

  • Confidential case: Lead counsel in preparation for litigation under BPCIA for biosimilar manufacturer.
  • Novartis Pharmaceuticals Corp.: Lead counsel in ANDA litigation against multiple generic defendants enforcing patents covering Gilenya®, the first oral treatment for multiple sclerosis.
  • Novartis Pharmaceuticals Corp.: Lead counsel in inter partes review (IPR) defending patent covering Gilenya® against three petitioners before the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office.
  • Merck Sharp & Dohme: Lead counsel in a Delaware district court defense and related IPR against a formulation patent asserted by Mayne Pharmaceuticals based on sales of Merck’s Noxafil anti-fungal product.
  • Novartis Pharmaceuticals Corp.: Lead counsel in ANDA litigation against more than 20 generic defendants enforcing several patents covering Reclast®and Zometa®, treatments for osteoporosis and cancer.
  • Novartis Pharmaceuticals Corp.: Co-lead counsel in ANDA litigation against multiple generic defendants enforcing patents covering Exjade®, a medicine for treatment of iron overload resulting from blood transfusions.
  • Confidential client: Advice related to Biologics Price Competition and Innovation Act of 2009 (BPCIA) and defense against biosimilar challenges.
  • AbbVie, Inc.: Co-lead counsel in patent litigation asserting patents directed to human antibodies directed against the cytokine IL-12 (Stelara®) and methods to treat autoimmune diseases.
  • Confidential client: International arbitration related to patents covering gene sequencing devices and methods.
  • Alnylam, Inc.: Lead counsel in a patent interference before the Board of Patent Appeals and Interferences at the U.S. Patent and Trademark Office related to small interfering RNAs, siRNAs, used for the treatment of cancer.
  • Japanese Foundation for Cancer Research: Co-lead counsel in patent interference before the Board of Patent Appeal and Interferences at the U.S. Patent and Trademark Office related to nucleic acids encoding interferon-beta, one of the first human proteins cloned.
  • Cephalon, Inc.: ANDA litigation enforcing patents covering Provigil®, a drug used to aid in wakefulness.
  • Hologic, Inc.: Lead counsel in a patent interference before the Board of Patent Appeals and Interferences at the U.S. Patent and Trademark Office related to breast biopsy devices.

Publications:

  • Co-Author, “TC Heartland And Hatch-Waxman: Square Peg In Round Hole,” Law360, January 30, 2018.

EDUCATION

Fordham University - 1999 Juris Doctor

University of Pennsylvania - 1993 Doctor of Philosophy

University of Pennsylvania - 1987 Bachelor of Arts

ADMISSIONS

New York Bar

RECENT PUBLICATIONS

Firm News - October 8, 2020 | LMG Life Sciences Names 13 Partners as Stars
Firm News - September 22, 2020 | Thirteen Gibson Dunn Partners Recognized in Expert Guides’ Women in Business Law
Firm News - June 17, 2020 | Gibson Dunn Recognized in IAM Patent 2020
Firm News - June 8, 2020 | Jane Love Named Among Top Women in IP 2020
Firm News - April 1, 2020 | Jane Love Named a Health Care/Life Science Trailblazer
Firm News - November 13, 2019 | Law360 Names Nine Gibson Dunn Partners as 2019 MVPs
Firm News - October 7, 2019 | LMG Life Sciences Names 12 Partners as Stars
Firm News - May 21, 2019 | Gibson Dunn Recognized in 2019 Managing IP Handbook
Firm News - October 31, 2018 | LMG Life Sciences Recognizes Gibson Dunn in Six Practices and Names 11 Lawyers Stars
Firm News - July 2, 2018 | Gibson Dunn Recognized in 2018 Managing IP Handbook
Firm News - June 8, 2018 | Jane Love Recognized by LMG Americas Women in Business
Article - January 30, 2018 | TC Heartland and Hatch-Waxman: Square Peg in a Round Hole
Firm News - January 12, 2018 | Law360 Names Jane Love a Life Sciences MVP
  • Sitemap
  • Client Extranet
  • Legal Notices
  • Privacy Policy
  • Cookie Notice
  • Contact Us
©Gibson, Dunn & Crutcher LLP 2021. All rights reserved.
Top
This website uses cookies to provide analytics on user traffic. By continuing to browse our website, you consent to our use of cookies as set forth in our Cookie Policy. However you may visit Cookie Settings to customize your consent.
Cookie SettingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Analytics

Cookies that tie into analytics systems, such as Google Analytics, YouTube and Vimeo analytics for embedded video, etc. The following are the cookies installed by the service: _ga, _gid, collect, vuid

Performance

These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is aggregated and therefore anonymous. It is only used to improve how a website works. The following cookie is installed by the Google Analytics service: _gat

Save & Accept